Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Drug & Device News

By ALM Staff | Law Journal Newsletters |
February 27, 2014

Pharmaceuticals: Common-Law Claims Allowed in PA

In a 47-page opinion, Pennsylvania's Supreme Court recently announced in Lance v. Wyeth that a right of action for defective drug design exists in the state, in addition to claims for manufacturing defects and inadequate warnings.

The Lance case was brought by the mother of a woman who died after taking the drug Redux, a diet pill manufactured by Wyeth Pharmaceuticals. The woman took the pills for just four months, in early 1997. Redux was taken off the market in September 1997. The suit alleges that the company was negligent in designing the drug, and in testing and marketing it. Wyeth sought dismissal of those claims, saying it had complied with federal regulations. It also asserted the defense of the learned intermediary doctrine: that the claimants did not have a case against it because the deceased's doctor had prescribed the medication. And the company tried to persuade the court that it was good policy to restrict the extent of liability drug manufacturers may face in product liability suits, in order to ensure the development and continued availability of beneficial drug products.

The court found that these arguments were not enough to forestall application of traditional civil liability to the company. Writing for the majority, Justice Thomas G. Saylor stated, “A subtext of Wyeth's positions … is that the likelihood that a pharmaceutical company would actually tender an essentially worthless and dangerous drug into commerce is so minimal, and the burden of responding to meritless claims so great, that it is not sound to preserve an avenue for redress even for legitimate claims.” He continued,' “We are asked to curtail an avenue of traditional, fault-based tort liability as an all-or-nothing proposition. Based on the presentation and record before us, however, we are unable to see with reasonable clarity the results of such decision and to say with reasonable certainty that the change will serve the best interest of society. … Accordingly, we are not in a position to make a responsible, substantive change in the law.”

Howard Bashman, one of the plaintiff's attorneys, says that the ruling may well affect other drug injury claims nationwide: “Not only does this confirm the existence of these claims in Pennsylvania law, but it may lay the groundwork in other states to consider the availability of claims like these.”

Risperdal Lawsuit Filings on the Rise

Lawsuit filings concerning the antipsychotic drug Risperdal ' which plaintiffs claim causes males to grow female breasts (gynecomastia) and increases the risk of pituitary tumors ' are still going strong.

Philadelphia Court of Common Pleas Judge Arnold L. New, supervising judge of the trial division's civil section and coordinating judge of the Complex Litigation Center, says that about 200 such cases are currently active, with Sheller P.C. serving as the principal plaintiffs' firm. Stephen Sheller, who founded the Sheller firm, says that the cases against Johnson & Johnson include failure-to-warn claims. “We have a group of cases coming into trial in July. Right now we're getting contacted by other attorneys referring to us. We have all the experts and documents,” Sheller said. He added that in the future, “we'll probably have at least a thousand cases.”

Food for Thought: Two Drug Names May Increase Potential for Error

In an article written by oncology nurse Theresa Brown for The New York Times, the author questions the advisability of our current drug-naming system, which often gives one medication both a brand-name and generic identification. Brown, Theresa, “One Drug, Two Names, Many Problems,” The New York Times, 12/1/13, available at http://nyti.ms/1khzgqv. She points out that, with two names, it is easy for practitioners to get confused and order the wrong medication for a patient, particularly in an emergency situation.'

Gastric Acid Reducing Medications May Cause Vitamin Deficiency

A study published in the Journal of the American Medical Association indicates that the long-term (more than two years) use of certain medications for reducing gastric acid may make a consumer more likely to have a vitamin B12 deficiency. Lam, Jameson R., et al., “Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency,” JAMA. 2013;310(22):2435-2442.doi:10.1001/jama.2013.280490.

'

'

Pharmaceuticals: Common-Law Claims Allowed in PA

In a 47-page opinion, Pennsylvania's Supreme Court recently announced in Lance v. Wyeth that a right of action for defective drug design exists in the state, in addition to claims for manufacturing defects and inadequate warnings.

The Lance case was brought by the mother of a woman who died after taking the drug Redux, a diet pill manufactured by Wyeth Pharmaceuticals. The woman took the pills for just four months, in early 1997. Redux was taken off the market in September 1997. The suit alleges that the company was negligent in designing the drug, and in testing and marketing it. Wyeth sought dismissal of those claims, saying it had complied with federal regulations. It also asserted the defense of the learned intermediary doctrine: that the claimants did not have a case against it because the deceased's doctor had prescribed the medication. And the company tried to persuade the court that it was good policy to restrict the extent of liability drug manufacturers may face in product liability suits, in order to ensure the development and continued availability of beneficial drug products.

The court found that these arguments were not enough to forestall application of traditional civil liability to the company. Writing for the majority, Justice Thomas G. Saylor stated, “A subtext of Wyeth's positions … is that the likelihood that a pharmaceutical company would actually tender an essentially worthless and dangerous drug into commerce is so minimal, and the burden of responding to meritless claims so great, that it is not sound to preserve an avenue for redress even for legitimate claims.” He continued,' “We are asked to curtail an avenue of traditional, fault-based tort liability as an all-or-nothing proposition. Based on the presentation and record before us, however, we are unable to see with reasonable clarity the results of such decision and to say with reasonable certainty that the change will serve the best interest of society. … Accordingly, we are not in a position to make a responsible, substantive change in the law.”

Howard Bashman, one of the plaintiff's attorneys, says that the ruling may well affect other drug injury claims nationwide: “Not only does this confirm the existence of these claims in Pennsylvania law, but it may lay the groundwork in other states to consider the availability of claims like these.”

Risperdal Lawsuit Filings on the Rise

Lawsuit filings concerning the antipsychotic drug Risperdal ' which plaintiffs claim causes males to grow female breasts (gynecomastia) and increases the risk of pituitary tumors ' are still going strong.

Philadelphia Court of Common Pleas Judge Arnold L. New, supervising judge of the trial division's civil section and coordinating judge of the Complex Litigation Center, says that about 200 such cases are currently active, with Sheller P.C. serving as the principal plaintiffs' firm. Stephen Sheller, who founded the Sheller firm, says that the cases against Johnson & Johnson include failure-to-warn claims. “We have a group of cases coming into trial in July. Right now we're getting contacted by other attorneys referring to us. We have all the experts and documents,” Sheller said. He added that in the future, “we'll probably have at least a thousand cases.”

Food for Thought: Two Drug Names May Increase Potential for Error

In an article written by oncology nurse Theresa Brown for The New York Times, the author questions the advisability of our current drug-naming system, which often gives one medication both a brand-name and generic identification. Brown, Theresa, “One Drug, Two Names, Many Problems,” The New York Times, 12/1/13, available at http://nyti.ms/1khzgqv. She points out that, with two names, it is easy for practitioners to get confused and order the wrong medication for a patient, particularly in an emergency situation.'

Gastric Acid Reducing Medications May Cause Vitamin Deficiency

A study published in the Journal of the American Medical Association indicates that the long-term (more than two years) use of certain medications for reducing gastric acid may make a consumer more likely to have a vitamin B12 deficiency. Lam, Jameson R., et al., “Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12 Deficiency,” JAMA. 2013;310(22):2435-2442.doi:10.1001/jama.2013.280490.

'

'

This premium content is locked for Entertainment Law & Finance subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
Major Differences In UK, U.S. Copyright Laws Image

This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.

Strategy vs. Tactics: Two Sides of a Difficult Coin Image

With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.

The Article 8 Opt In Image

The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.

Removing Restrictive Covenants In New York Image

In Rockwell v. Despart, the New York Supreme Court, Third Department, recently revisited a recurring question: When may a landowner seek judicial removal of a covenant restricting use of her land?

The Benefits of Blockchain for e-Discovery and Data Preservation Image

As businesses across various industries increasingly adopt blockchain, it will become a critical source of discoverable electronically stored information. The potential benefits of blockchain for e-discovery and data preservation are substantial, making it an area of growing interest and importance.